Nevertheless, by describing the kinetics of both GFAP and antibodies against NR2 RNMDA in the following 2 weeks after stroke we demonstrated that used together, the biomarkers can discriminate between the two types of lesions even after the first 12 hrs. The gene discussed is GFAP; the disease is Stroke.